Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

被引：0
|
作者：
Kris, M. G. [1 ]
Riely, G. J. [1 ]
Azzoli, C. G. [1 ]
Heelan, R. T. [1 ]
Krug, L. M. [1 ]
Pao, W. [1 ]
Milton, D. T. [1 ]
Moore, E. [1 ]
Rizvi, N. A. [1 ]
Miller, V. A. [1 ]
机构：
[1] Memor Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7575
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial
    Zhixue Fu
    Xu Yang
    Wenqing Wang
    Lei Deng
    Tao Zhang
    Nan Bi
    Xiaozhen Wang
    Dongfu Chen
    Zongmei Zhou
    Luhua Wang
    Jun Liang
    Radiation Oncology, 15
  • [22] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations.
    Choi, Moon Ki
    Hong, Jung Yong
    Chang, Won Jin
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Lim, Sung Hee
    Lee, Ji Yun
    Do, Ingu
    Chol, Yoon-La
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Kounchil
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] A chinese, multicenter, phase II trial of gefitinib (IRESSA) in patients with non-small cell lung cancer who had failed previous chemotherapy
    Guan, Z
    Zhang, L
    Li, L
    Jiang, G
    Liu, X
    Chu, D
    Li, W
    LUNG CANCER, 2005, 49 : S246 - S246
  • [24] Phase I study of daily or weekly RAD001 (R, everolimus) in combination with pemetrexed (P) in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy
    Vansteenkiste, Johan
    Solomon, Ben
    Boyer, Michael
    Wolf, Juergen
    Miller, Neil
    Di Scala, Lilla
    Petrovic, Katarina
    Dimitrijevic, Sasa
    Anrys, Beatrijs
    Laack, Eckart
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S446 - S446
  • [25] Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer (MBC)
    Mayer, I. A.
    Means-Powell, J.
    Abramson, V. G.
    Shyr, Y.
    Balko, J. M.
    Kuba, M. G.
    Gharavii, H. M.
    Schlabach, L.
    Arteaga, C. L.
    Pietenpol, J. A.
    CANCER RESEARCH, 2011, 71
  • [26] ANALYSIS OF MTOR SIGNALING PATHWAY BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH EVEROLIMUS AND DOCETAXEL IN A PHASE II CLINICAL TRIAL.
    Owonikoko, Taofeek K.
    Ramalingam, Suresh
    Subramanian, Janakiraman
    Sica, Gabriel
    Chen, Zhengjia
    Behera, Madhusmita
    Rogerio, Jaqueline
    Saba, Nabil
    Tighiouart, Mourad
    Gal, Anthony
    Govindan, Ramaswamy
    Khuri, Fadlo R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1039 - S1040
  • [27] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [28] A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
    Amato, Robert J.
    Jac, Jaroslaw
    Giessinger, Sarah
    Saxena, Somyata
    Willis, James P.
    CANCER, 2009, 115 (11) : 2438 - 2446
  • [29] A PHASE II STUDY OF ERLOTINIB FOR PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD FAILED GEFITINIB
    Lee, D. H.
    Kim, H. T.
    Kim, S.
    Suh, C.
    Lee, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [30] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
    Choi, Moon Ki
    Hong, Jung Yong
    Chang, Won Jin
    Kim, Moon Jin
    Kim, Sung Min
    Jung, Hyun Ae
    Do, In-Gu
    Choi, Yoon-la
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1229 - 1236
12345